Charles River Laboratories International, Inc. $CRL Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 17.4% in the 1st quarter, HoldingsChannel reports. The firm owned 43,471 shares of the medical research company’s stock after purchasing an additional 6,444 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Charles River Laboratories International were worth $7,499,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International during the 4th quarter valued at $42,000. Sfam LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $43,000. Activest Wealth Management boosted its position in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $46,000. 98.91% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on CRL. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research report on Monday, July 20th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Finally, Morgan Stanley raised their price objective on Charles River Laboratories International from $220.00 to $260.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus price target of $220.75.

Charles River Laboratories International Stock Up 1.2%

Shares of NYSE:CRL opened at $233.62 on Wednesday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The company has a market cap of $11.25 billion, a PE ratio of -62.13, a price-to-earnings-growth ratio of 2.57 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $242.73. The firm has a 50 day simple moving average of $209.54 and a 200 day simple moving average of $188.12.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. During the same quarter last year, the business posted $2.34 EPS. The company’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.